EPZ-6438 (Tazemetostat)

Catalog No. A12712

EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. It induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.
  • Wang Z, .et al. Targeting EZH 2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma, J Cell Mol Med, 2019, May 13 PMID: 31087496
  • Theresa Baker, .et al. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors, Oncotarget, 2015, Oct 20; 6(32): 32646-32655 PMID: 26360609
Catalog Num A12712
M. Wt 572.74
Formula C34H44N4O4
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1403254-99-8
Synonyms EPZ6438, EPZ 6438
SMILES CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. It induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.
Targets
EZH2 (Cell-free assay) EZH2 (Cell-free assay)
2.5 nM(Ki)2.5 nM(Ki)
In vitro DMSO 29 mg/mL (50.63 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 17.46 mL 87.3 mL 174.6 mL
0.5 mM 3.49 mL 17.46 mL 34.92 mL
1 mM 1.75 mL 8.73 mL 17.46 mL
5 mM 0.35 mL 1.75 mL 3.49 mL

*The above data is based on the productmolecular weight 572.74. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.